Navigation Links
More screening needed to identify depression, vision loss after mild stroke
Date:10/2/2011

OTTAWA, Oct. 3, 2011 -- On the surface they appear unaffected, but people who have mild strokes may live with hidden disabilities, including depression, vision problems and difficulty thinking, according to a study released today at the Canadian Stroke Congress.

The study calls for new guidelines for the treatment and management of mild strokes, which account for two-thirds of all strokes and usually involve a hospital stay of one to five days. Co-author Annie Rochette, Ph.D, of the University of Montreal, and her research team interviewed 200 people in Quebec, Ontario and Alberta within the first six weeks of their stroke.

"There is no such thing as a mild stroke," says Dr. Rochette, who describes high rates of sleeplessness and depression among study participants almost a quarter of whom were clinically depressed. "These patients face huge challenges in their daily lives." Study participants reported a significantly poorer perceived quality of life.

Participants in the study were generally younger than people who have severe strokes. The mean age of study participants was 62. Seventy-five per cent of severe strokes occur in people over age 65.

People interviewed worried about returning to work (41 per cent were working before their stroke), taking care of their families and being able to drive. Yet, few were screened for visual or cognitive impairments, which are not as easily detected as impairments in movement, before leaving hospital or provided with post-stroke rehabilitation.

Nearly 25 per cent of mild stroke patients only visited the emergency room. Occupational therapists, neuropsychologists or speech therapists, who typically do these types of screenings, do not usually see mild stroke patients, says Dr. Rochette.

"Patients are told to see their family doctor, but given no other tools or rehabilitation," says Dr. Rochette. "When they go to drive again some people are too afraid to get behind t
'/>"/>

Contact: Cathy Campbell
cathy@canadianstrokenetwork.ca
613-852-2303
Heart and Stroke Foundation of Canada
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Do Men Need Colon Cancer Screening Earlier Than Women Do?
2. Fatalism Keeps Many From Colon Cancer Screening
3. Cancer screening rates lower among those with fatalistic attitudes
4. High-risk, underserved women benefited from MRI screening for breast cancer
5. Parents anxiety about newborn screening results does not lead to increased health care use
6. Screening Lots of Lymph Nodes Little Help for Colon Cancer Patients
7. Screening for HPV persistence and cervical cancer risk
8. Troubled Teens Spotted in Routine School Screenings: Study
9. Single flexible sigmoidoscopy screening associated with reduced colorectal cancer
10. Annual cervical cancer screening persists, despite recommended guidelines
11. New prostate cancer screening test shows promise for diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013 The deadline to ... this Friday, June 21 at midnight ET. This ... and innovative people who’ve raised the bar on ... http://www.minonline.com/ima . , Any consumer and b2b ... is eligible to enter. Additionally, advertising agencies and ...
(Date:6/19/2013)... Lake City, UT (PRWEB) June 19, 2013 ... companies : , In July 2013, Orriant is ... their participation rates, and maintain compliance with regulations. ... allowing employees to receive wellness incentives if their ... has announced they have been compliant with these ...
(Date:6/19/2013)... Amber Roberson with the Robert ... Native Care Health, LLC and Medcase, LLC, became ... (NAHU) new professional development course on the Patient ... education course for agents has been approved in ... education credits from the Missouri Department of Insurance. ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 According to ... for Surviving Weekend Sunburn,” it is not uncommon for a ... the summer months. A person is likely to forget to ... , which is both dry and itchy. When this occurs, ... (Go to goo.gl/gDyjP). , “Most people do not realize that ...
(Date:6/19/2013)... international study led by researchers at The University of ... continues to show remarkable promise for the treatment of ... most recent interim findings of the 18-center Phase 2 ... Journal of Medicine . Previous interim findings were presented ... Hematology Annual Meeting and Exposition. , Unprecedented ...
Breaking Medicine News(10 mins):Health News:Entry Deadline for min’s Integrated Marketing Awards Is This Friday, June 21 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:RWI Benefits, LLC Becomes PPACA Certified 2Health News:Skin Care – How to treat Sunburn 2Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2
... alert in India's northeast asking authorities to take ... outbreak in Bangladesh and Myanmar, officials said ... Tripura government has made arrangements for free consultation ... sub-divisions, especially those along the bordering areas," Tripura's ...
... known as a poison that can kill, arsenic also can ... leukemia , a new study out Saturday found. ... we give (arsenic) earlier in the course of treatment," said ... in North Carolina, and the lead author of the research ...
... issue of JAMA, has identified novel genetic mutations linked ... these mutations are due to both independent mutational events ... to coincide with its presentation at the annual meeting ... ,According to background information in the article, gastric cancer ...
... CHICAGO, According to a University of Pittsburgh Medical Center ... American Society of Clinical Oncology (ASCO) in Chicago and ... patients treated for follicular lymphoma, a slow-growing type of ... ,Over 90 percent of study patients responded ...
... CEGE) today announced follow-up data from a Phase 2 ... was conducted by the Johns Hopkins Sidney Kimmel Cancer ... pancreatic cancer who received GVAX after surgical resection of ... overall survival for these patients was previously reported to ...
... receiving end, even if it is all subtle, as in ... to pin down is more dangerous to mental health ... immigrants living in Canada. ,"We found that the ... distress such as symptoms of depression and anxiety," said lead ...
Cached Medicine News:Health News:Researchers Identify Genetic Mutations for Hereditary Diffuse Gastric Cancer 2Health News:Researchers Identify Genetic Mutations for Hereditary Diffuse Gastric Cancer 3Health News:Lymphoma Patients Maybe Helped by Adding Radioimmunotherapy to Chemo 2Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 2Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 3Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 4Health News:Koreans in Canada Feel Put Down by Subtle Racism 2
(Date:6/19/2013)... 2013   Nektar Therapeutics (Nasdaq: NKTR ... liability (HAL) study for NKTR-181, a first-in-class, opioid ... brain.  This slow rate of entry is designed to reduce ... addiction to current opioid analgesics. 1 In the study ... to placebo in "drug liking" and "feeling high" scores and ...
(Date:6/19/2013)... Calif. , June 19, 2013 BD Biosciences, ... BDX ), a leading global medical technology company, today ... Analyzer , the latest in its line of high-performance research ... Analyzer delivers high-performance multicolor analysis with the most compact footprint ... 73.7 cm) and a height of 30" (76.2 cm). Recognizing ...
(Date:6/19/2013)... ZIONA, Israel , June ... announced that results from a phase I study in ... in advanced Parkinson,s patients, of ND0612, were presented at ... Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug formula ... delivery patch that would maintain constant levodopa plasma concentrations. ...
Breaking Medicine Technology:Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6
... ARBOR, Mich., Nov. 11, 2011 Adeona ... developer of innovative medicines for serious central nervous system ... estriol), will be utilized in a new Phase II ... cognitive dysfunction observed in female multiple sclerosis (MS) patients. ...
... 11, 2011 Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ... Officer, will be presenting at the Lazard Capital Markets 8th ... New York City. Mr. Bentsur,s presentation is scheduled to take ... A live audio webcast of Mr. Bentsur,s presentation ...
Cached Medicine Technology:Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 2Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 3Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 4Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 5Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference 2
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available....
Inquire...
Medicine Products: